Unaudited Financial result of the company for the quarter ended June 30, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Link Pharma Chem Ltd reported Q1 FY26 revenue from operations of Rs 781.48 lakhs, down from Rs 884.63 lakhs in Q1 FY25, a YoY decline of about 12%. However, profit after tax rose to Rs 40.19 lakhs from Rs 29.64 lakhs in the same quarter last year, thanks to lower raw material costs. Earnings per share improved to Rs 0.91 versus Rs 0.67 YoY. Total income stood at Rs 802.40 lakhs, and profit before tax came in at Rs 50.97 lakhs. The board also approved the re-appointment of Mrs. Rachna Manav Ghai as Woman Independent Director for a second 5-year term starting September 14, 2025. The results were reviewed by statutory auditor CNK & Associates LLP with an unqualified review report.
Mixed quarter for shareholders — top line shrank YoY but margins and bottom line improved, suggesting better cost control. The independent director re-appointment is routine and unlikely to move the stock; focus will remain on whether revenue recovers in coming quarters.